Priscilla Fowler, MD
Ophthalmology · Birmingham, ALNPI 1851398093
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,970 of the $5,720 with a category attached, or 86.9%. It is spread thinly across 18 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,655, more than ten times the $130 reported in 2019.
Across 183 payments — averaging $31.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alcon$869
- Biotissue Holdings Inc.$835
- Sun Pharmaceutical Industries Inc.$566
- Oyster Point Pharma, Inc.$504
- Johnson & Johnson Surgical Vision, Inc.$426
- plus $1K from 12 others
What the payments were for
- Consulting fees$75013%
- Food & beverage$4,97087%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 25 | $1,217 |
| Alcon | 34 | $869 |
| Biotissue Holdings Inc. | 14 | $835 |
| Sun Pharmaceutical Industries Inc. | 26 | $566 |
| Oyster Point Pharma, Inc. | 19 | $504 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $426 |
| Bausch & Lomb Americas Inc. | 15 | $237 |
| Novartis | 12 | $237 |
| Harrow Eye, LLC | 10 | $235 |
| Glaukos Corporation | 3 | $185 |
| NEW World Medical,inc. | 3 | $178 |
| Sight Sciences, Inc. | 2 | $66 |
| Dompe US, Inc. | 2 | $48 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $47 |
| Thea Pharma Inc. | 1 | $22 |
| Kala Pharmaceuticals, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESTASIS$750
- Kahook Dual Blade$136
- Clearpath$136
- Ahmed Glaucoma Valve$136
- Streamline$136
- Via360$136
- Tecnis IOL$119
- TYRVAYA$115
- Prokera$106
- AmnioGraft$106
How this compares
$5,720 in reported general payments places this provider in the 80th percentile of 197 ophthalmology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 412 | $423,749 |
| RestasisCyclosporine | 337 | $370,876 |
| Cyclosporine | 202 | $137,487 |
| TyrvayaVarenicline Tartrate | 105 | $96,318 |
| MieboPerfluorohexyloctane/Pf | 54 | $39,827 |
| Prednisolone Acetate | 420 | $19,533 |
| CequaCyclosporine | 23 | $18,534 |
| ErythromycinErythromycin Base | 821 | $10,189 |
| Fluorometholone | 118 | $9,577 |
| MoxifloxacinMoxifloxacin Hcl | 125 | $6,720 |
| Brimonidine Tartrate | 45 | $3,652 |
| Loteprednol Etabonate | 14 | $3,558 |
| ValacyclovirValacyclovir Hcl | 93 | $3,298 |
| Doxycycline Hyclate | 124 | $2,973 |
| Latanoprost | 175 | $2,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $237 | $463,576466 claims |
| AbbVieRestasis | $1,217 | $370,876337 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $504 | $96,318105 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $566 | $18,53423 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $47 | $3,55814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 197 ophthalmology providers in Alabama.
Other ophthalmology in Birmingham
- Kristin BainsBirmingham$40K
- Lindsay RhodesBirmingham$18K
- James LewisBirmingham$15K
- Marc MichelsonBirmingham$9K
- Jennifer MichelsonBirmingham$8K
- John MasonBirmingham$7K
- Walter ParkerBirmingham$6K
- Mark BearmanBirmingham$5K
- Michael AlbertBirmingham$5K
- Kathleen GeeBirmingham$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.